含新药诱导化疗序贯自体造血干细胞移植及维持治疗多发性骨髓瘤:300例单中心回顾性研究
该单中心研究回顾性分析近15年接受含新药诱导化疗序贯自体造血干细胞移植及维持治疗的300例多发性骨髓瘤患者,诱导、移植、维持后完全缓解率分别为35.3%、55.2%、72.4%,≥非常好的部分缓解率分别为80.0%、89.2%、93.4%,中位疾病进展时间78.7个月,中位总生存109.0个月,但高危细胞遗传学患者获益不明显。
要点
- 含新药诱导序贯自体移植及维持治疗的中位总生存达109.0个月。
- 治疗不同阶段获得完全缓解和微小残留病阴性者疾病进展时间与总生存更长。
- 高危细胞遗传学患者即使诱导获完全缓解,疾病进展时间仍短于标危患者。
核心结论
- 含新药诱导化疗序贯自体造血干细胞移植及维持治疗的多发性骨髓瘤整体策略具有较好远期疗效,中位生存接近10年,但高危细胞遗传学患者获益不明显。
研究设计与样本
- 单中心回顾性及前瞻性分析近15年接受含新药方案诱导化疗序贯自体造血干细胞移植及维持治疗的300例多发性骨髓瘤患者。
主要发现
- 诱导化疗、自体造血干细胞移植、维持治疗后的完全缓解率分别为35.3%、55.2%、72.4%,≥非常好的部分缓解率分别为80.0%、89.2%、93.4%。
- 三药诱导方案的≥非常好的部分缓解率和总反应率高于双药诱导方案;PAD方案与RAD方案的完全缓解率、≥非常好的部分缓解率及总反应率差异均无统计学意义,但获益速度不同。
- 诱导化疗、自体造血干细胞移植、维持治疗后流式细胞术微小残留病阴性患者在完全缓解患者中的占比分别为18.8%(54例)、41.4%(109例)、58.7%(142例)。
- 中位随访时间48.5(7.4~171.3)个月,全部患者中位疾病进展时间78.7个月,中位总生存109.0个月;R-ISS Ⅰ、Ⅱ、Ⅲ期患者中位疾病进展时间分别为111.8、77.4、30.6个月,中位总生存分别为118.8、91.4、48.5个月。
- 多因素分析显示R-ISS分期在不同治疗阶段均为疾病进展时间和总生存的不良预后因素,治疗后获得的疗效成为新的独立预后因素。
关键数值与推荐
- 在治疗不同阶段获得完全缓解和微小残留病阴性的患者,其疾病进展时间和总生存均较未获得完全缓解和微小残留病阴性者明显延长。
- 诱导化疗阶段获得完全缓解的高危细胞遗传学患者疾病进展时间短于不伴高危细胞遗传学患者;诱导化疗阶段获得微小残留病阴性的高危细胞遗传学患者疾病进展时间与不伴高危细胞遗传学患者差异无统计学意义。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To examine the survival and influential factors of an integrated approach of novel agents, autologous hematopoietic stem cell (auto-HSCT) , and maintenance therapy in patients with multiple myeloma (MM) patients from a single center over the past 15 years. Methods: In our center, 300 MM patients who received an integrated strategy of new agents, auto-HSCT, and maintenance therapy over 15 years were retrospectively and prospectively analyzed. Results: The complete remission rates (CR) and ≥very good partial remission rates (VGPR) following induction therapy, transplantation, and maintenance therapy were respectively 35.3% and 55.2% , 72.4% and 80.0% , 89.2% , and 93.4% . When compared to patients receiving double-drug induction, the ≥VGPR and ORR of patients receiving triple-drug induction were improved. No difference existed in CR, ≥VGPR, and ORR between the PAD (bortezomib + liposome doxorubicin+ dexamethasone) and RAD (lenalidomide + liposome doxorubicin + dexamethasone) regimens, but the benefits speed differed. The negative rate of flow minimal residual disease following induction, transplantation, and maintenance was 18.8% (54 cases) , 41.4% (109 cases) , and 58.7% (142 cases) , respectively. The median time to progress (TTP) was 78.7 months and the median overall survival (OS) was 109 months. The median TTP for RISS-Ⅰ-Ⅲ patients were 111.8 months, 77.4 months, and 30.6 months, and the median OS was 118.8 months, 91.4 months, and 48.5 months, respectively. At various points during treatment, the TTP and OS of patients obtaining CR and MRD negative were longer than those of patients who did not obtain CR and MRD negative. TTP was noticeably shorter in high-risk cytogenetic patients compared to standard-risk patients even when CR was acquired during induction. There was no difference in TTP between patients with high-risk cytogenetics and those with standard-risk cytogenetics if MRD negative was acquired during induction. According to a multivariate analysis, the R-ISS stage was a poor predictor of TTP and OS at various treatment intervals. Therapeutic effectiveness was a newly independent prognostic factor following treatment. Conclusion: A median survival of almost 10 years is possible for MM patients who receive an integrated strategy of induction regimens followed by auto-HSCT and maintenance therapy, which significantly improves prognosis. However, this approach did not significantly benefit high-risk cytogenetic MM patients. 目的: 分析含新药诱导化疗序贯自体造血干细胞移植(auto-HSCT)、维持治疗策略治疗多发性骨髓瘤(MM)患者的预后及影响因素。 方法: 对近15年接受含新药方案诱导化疗序贯auto-HSCT、维持治疗的300例MM患者进行回顾性分析。 结果: 诱导化疗、auto-HSCT、维持治疗后的完全缓解(CR)率分别为35.3%、55.2%、72.4%,≥非常好的部分缓解(VGPR)率分别为80.0%、89.2%、93.4%;PAD方案(硼替佐米+脂质体阿霉素+地塞米松)诱导化疗的≥VGPR率、总反应率(ORR)均高于VD方案(硼替佐米+地塞米松),PAD方案和RAD方案(来那度胺+脂质体阿霉素+地塞米松)相比,CR率、≥VGPR率以及ORR差异均无统计学意义;诱导化疗、auto-HSCT、维持治疗后流式细胞术微小残留病(MRD)阴性患者在CR患者中的占比分别为18.8%(54例)、41.4%(109例)、58.7%(142例)。中位随访时间48.5(7.4~171.3)个月,全部MM患者中位疾病进展时间(TTP)为78.7个月,中位总生存(OS)时间为109.0个月;R-ISS Ⅰ、Ⅱ、Ⅲ期患者的中位TTP时间分别为111.8、77.4、30.6个月,中位OS时间分别为118.8、91.4、48.5个月。在治疗的不同阶段获得CR和MRD阴性患者的TTP、OS时间均较未获得CR和MRD阴性患者明显延长。在诱导化疗阶段获得CR的伴有高危细胞遗传学患者,其TTP短于不伴高危细胞遗传学患者;诱导化疗阶段获得MRD阴性的高危细胞遗传学患者,其TTP和不伴高危细胞遗传学患者相比差异无统计学意义。多因素分析显示,R-ISS分期在不同治疗阶段都是影响TTP和OS的不良预后因素;患者在接受治疗后,治疗获得的疗效就成为新的独立不良预后因素。 结论: 含新药诱导化疗序贯auto-HSCT、维持治疗的MM整体治疗策略具有较好的远期疗效,但高危MM患者获益不明显。.
引用
- Liu JR, Gu JL, Huang BH, et al. [New agents-based induction chemotherapy followed by autologous stem cell transplantation and maintenance treatment strategy for multiple myeloma: a single center retrospective study of 300 cases]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 36709105. doi:10.3760/cma.j.issn.0253-2727.2022.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。